VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, explains how the PHE885 CAR-T construct differs from existing BCMA-directed CAR-T therapies and highlights the results of a Phase I trial evaluating this product at different dose levels (NCT04318327). Overall, the study reported early evidence of promising activity and expansion of the CAR-Ts in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter